As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Eupraxia Pharmaceuticals Inc. The largest reported stake is Joseph S. Freedman's, at 9%. 8 filings are on record since September 26, 2025 (Schedule 13D/A, March 16, 2026).
Sell to companies like Eupraxia Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Manchester Management Company, LLC · Sole voting: 0 · Shared voting: 2,634,048 · Sole dispositive: 0 · Shared dispositive: 2,634,048 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Morgan C. Frank · Percent: 7.7% · SCHEDULE 13G/A
- · Reporting person: Joseph S. Freedman · Sole voting: 4,309,205 · Shared voting: 1,534,010 · Sole dispositive: 4,309,205 · Shared dispositive: 1,534,010 · SCHEDULE 13D/A, 2026-03-16
- · Holder: Morgan C. Frank · Percent: 9.2% · SCHEDULE 13G/A
- · Holder: Robert Disbrow · Percent: 7% · SCHEDULE 13G/A
Eupraxia Pharmaceuticals Inc. has 8 Schedule 13D or 13G filings on record since 2025-09-26. 3 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9% | 5,843,215 | SCHEDULE 13D/A, 2026-03-16 | 2026-03-13 | |
| Beutel, Goodman & Co Ltd. | 8% | 4,058,899 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| 7% | 3,568,150 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| 4.5% | 2,772,341 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind Eupraxia Pharmaceuticals Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Eupraxia Pharmaceuticals Inc. and the records around it.
Eupraxia Pharmaceuticals Inc. elsewhere on the record
Companies that share a holder
- MANCHESTER MANAGEMENT COMPANY, LLC also filed stake reports on 2 other companies: Alpha Cognition Inc. (Sep 2026), SANUWAVE Health, Inc. (Dec 2025)
- Beutel, Goodman & Co Ltd. also filed stake reports on 4 other companies: Boyd Group Services Inc. (Nov 2026), HARLEY-DAVIDSON, INC. (Feb 2026), Docebo Inc. (Jan 2026)
Watch Eupraxia Pharmaceuticals Inc.
Get an email when Eupraxia Pharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Eupraxia Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Eupraxia Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eupraxia Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Joseph S. Freedman | 4,309,205 | 1,534,010 | 4,309,205 | 1,534,010 | SCHEDULE 13D/A, 2026-03-16 |
| Manchester Management Company, LLC | 0 | 2,634,048 | 0 | 2,634,048 | SCHEDULE 13G/A, 2026-08-13 |
| Manchester Management Pr, LLC | 0 | 2,634,048 | 0 | 2,634,048 | SCHEDULE 13G/A, 2026-08-13 |
| Manchester Explorer, L.P. | 0 | 2,511,121 | 0 | 2,511,121 | SCHEDULE 13G/A, 2026-08-13 |
| James E. Besser | 138,293 | 2,634,048 | 138,293 | 2,634,048 | SCHEDULE 13G/A, 2026-08-13 |
| Morgan C. Frank | 153,659 | 2,511,121 | 153,659 | 2,511,121 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Eupraxia Pharmaceuticals Inc. by CUSIP 29842P105 and gives its principal executive office as 201-2067 CADBORO BAY RD., VICTORIA (SCHEDULE 13G/A, 2026-08-13).
Source of funds (Item 3)
Item 3 is hereby amended to add the following: On February 20, 2026, the Reporting Person purchased 275,517 Common Shares, and his spouse purchased 4,483 Common Shares, in an underwritten public offering (the "2026 Offering") at a price of $7.00 per share for an aggregate purchase price of $1,960,000. The source of the funds used to pay the purchase price was the Reporting Person's personal funds for the 275,517 Common Shares and his spouse's personal funds for the 4,483 Common Shares purchased by her.Joseph S. Freedman, SCHEDULE 13D/A, 2026-03-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-26 | Joseph S. Freedman | 10.2% | SCHEDULE 13D/A |
| 2025-11-13 | James E. Besser | 10.9% | SCHEDULE 13G |
| 2025-11-14 | Robert Disbrow | 7% | SCHEDULE 13G/A |
| 2025-11-14 | Beutel, Goodman & Co Ltd. | 8% | SCHEDULE 13G |
| 2026-02-17 | Morgan C. Frank | 9.2% | SCHEDULE 13G/A |
| 2026-03-16 | Joseph S. Freedman | 9% | SCHEDULE 13D/A |
| 2026-05-12 | Morgan C. Frank | 7.7% | SCHEDULE 13G/A |
| 2026-08-13 | James E. Besser | 4.5% | SCHEDULE 13G/A |
Questions about who owns Eupraxia Pharmaceuticals Inc.
Who owns Eupraxia Pharmaceuticals Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Eupraxia Pharmaceuticals Inc.: Joseph S. Freedman (9%, Schedule 13D/A, filed 2026-03-16), Beutel, Goodman & Co Ltd. (8%, Schedule 13G, filed 2025-11-14) and Robert Disbrow (7%, Schedule 13G/A, filed 2025-11-14).
Who are the largest shareholders of Eupraxia Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Eupraxia Pharmaceuticals Inc. on this page are Joseph S. Freedman (9%), Beutel, Goodman & Co Ltd. (8%) and Robert Disbrow (7%).
When did Joseph S. Freedman buy into Eupraxia Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Joseph S. Freedman on this page is the Schedule 13D/A, filed 2025-09-26, reporting 10.2%; its latest, Schedule 13D/A filed 2026-03-16, reports 9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Eupraxia Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.